The BMI threshold for Mounjaro on the NHS is higher than most people expect

The myth: any BMI over 30 qualifies you for NHS Mounjaro

This is the most common misreading, and it is understandable, the licensed indication for tirzepatide covers adults with a BMI of 30 or above (or 27 with a weight-related condition). That is the prescribing licence. The NHS commissioning criteria are a different, narrower thing, written by NICE and NHS England to manage capacity and cost. Plenty of people who are clinically eligible under the medicine's licence are not yet eligible for it through the NHS. The gap between those two things is what causes confusion.

NICE appraised tirzepatide in late 2024 and published its recommendation as TA1026. The recommendation is positive, but it is conditional: to qualify in the current first phase of rollout, a patient needs a BMI of 40 or above and four or more of the five named weight-related conditions, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Four conditions. Not one, not two. That is the bar as things stand.

Meeting the BMI figure alone gets you nowhere without the comorbidity count. And even meeting both does not guarantee a prescription, the patient must be referred into, and accepted by, a qualifying NHS programme, with wrap-around dietary and activity support as part of the package. Our guide to NHS Mounjaro access runs through each requirement in plain terms.

The phased rollout: what BMI will qualify in future

The access criteria are designed to loosen in stages as NHS capacity grows. The current phase, active from June 2025, requires BMI 40-plus and four qualifying conditions. A second cohort opened on 23 June 2026, extending eligibility to people with a BMI between 35 and 39.9 who still meet the four-condition requirement. A further expansion, planned for around March 2027, will bring in people with a BMI of 40 or above and three (rather than four) qualifying conditions.

That schedule can shift. NHS England and individual integrated care boards retain discretion over implementation timelines, and local variation is real, a GP practice in one area may have joined the relevant QOF scheme while one nearby has not. From 1 April 2026, GP practices can prescribe tirzepatide directly under the new GP contract, but participation is optional. If you want to understand the full process from referral to prescription, our page on how to get Mounjaro on the NHS explains each step clearly. NHS England's guidance on weight-management injections sets out the wrap-around care requirements that apply at every stage.

If you are timing an enquiry around a payday, a new month, or returning from holiday, bear in mind that NHS access hinges on where you sit in the rollout, not on when you apply.

The ethnic-background adjustment, often overlooked

NICE built an important correction into TA1026 that many people have not heard about. For adults from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, each BMI threshold in the guidance applies at 2.5 kg/m² lower than the headline figure. In practical terms: the first-phase BMI-40 threshold becomes 37.5 for those groups; the 35–39.9 band shifts to 32.5–37.4. The clinical reasoning is that body-fat distribution and cardiometabolic risk differ at a given BMI between ethnic groups, the same number on the scale carries different health implications.

This adjustment is part of the formal NICE recommendation, not a local policy. If you are in one of these groups and were told you do not meet the BMI threshold, it is worth checking whether that assessment applied the correct figure. A closer look at who qualifies for NHS Mounjaro covers this in more detail.

What to do if your BMI does not meet the NHS threshold

Most people asking this question are asking because they expect to fall short. The NHS criteria are strict by design, and that leaves a large group of people (clinically eligible under the medicine's licence, with real health reasons to lose weight) without an NHS route right now. There are two practical responses to that.

One is to wait: the rollout widens, and criteria that exclude you today may include you in 2027. The other is to explore private treatment. Mounjaro is available privately through a GPhC-registered online pharmacy following a full clinical assessment by a prescriber. The private eligibility criteria follow the licensed indication (BMI 30 or above, or 27 with a qualifying condition) which is broader than the NHS rules. If you want to understand whether that route suits your situation, this page covers private Mounjaro access at lower BMI, and our Mounjaro overview explains what treatment involves from the first consultation onwards.

Private treatment is not a workaround or a shortcut, it is a separate, fully regulated clinical pathway, with a prescriber, an identity check, and weight verification at every stage. If you would like to explore it, you can speak to our prescribers through a free consultation, reviewed the same day.